Clinical trials: Parkinson Disease(PD)
Colorectal Cancer
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer.
- Trial name
- NCT05064059
- Testing
- favezelimab/pembrolizumab, regorafenib, TAS-102
- Where
- 152 sites in United States, Australia and 19 more
- Volunteers
- 441 people
- Sponsor
- Merck Sharp & Dohme LLC
Lewy Body Dementia, Parkinson Disease
Anti-Diabetic Medications to Fight PD and LBD
The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
- Trial name
- NCT06263673
- Testing
- Sitagliptin, Dapagliflozin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Esophageal Cancer
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
This is an open-label, Phase 1/2 study to evaluate the safety of durvalumab (MEDI4736) in combination with oxaliplatin/capecitabine chemotherapy in metastatic/locally advanced oesophageal cancer (OC) and with neoadjuvant…
- Trial name
- NCT02735239
- Testing
- Durvalumab, Tremelimumab, Oxaliplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 73 people
- Sponsor
- Ludwig Institute for Cancer Research
Parkinson's Disease (PD)
An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites
The purpose of this study is to determine the rate and routes of excretion of OPC and the mass balance in urine, faeces and expired air.
- Trial name
- NCT02169427
- Testing
- OPC
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease
Pramipexole Conversion to Ropinirole Controlled Release (CR)
A conversion study of Mirapex (pramipexole) to Requip (ropinirole) controlled release (CR) in patients with Parkinson's disease to determine the appropriate conversion ratio and side effects related to the drug.
- Trial name
- NCT00275275
- Testing
- Requip PR, Mirapex
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Rajesh Pahwa, MD
Parkinson's Disease
Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease
Background: Long-term management of Parkinson's disease (PD) does not reach its full potential due to lack of knowledge about disease progression.
- Trial name
- NCT02474329
- Testing
- Clinical assessment, Fox Insight self-monitoring android app and falls detector
- Where
- Netherlands
- Volunteers
- 304 people
- Sponsor
- Radboud University Medical Center
Parkinson's Disease
Evaluation of Long-term Effect of Resonator Therapy on Parkinson's Disease (PD)
An extension study for subjects with prior participation in previous resonator studies using low level magnetic fields to treat some of the symptoms of idiopathic Parkinson's Disease.
- Trial name
- NCT00862537
- Testing
- Resonator Device
- Volunteers
- 18 people
- Sponsor
- pico-tesla Magnetic Therapies, LLC
Colorectal Neoplasms
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
- Trial name
- NCT03631407
- Testing
- Vicriviroc, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
Pivotal Study in Advanced Parkinsons Disease Patients
The general aim of this trial is to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for Unified Parkinsons Disease Rating Scale Parts II and III combined)…
- Trial name
- NCT00466167
- Testing
- Pramipexol Extended Release, Pramipexol Immediate Release
- Where
- 76 sites in Austria, Czechia and 12 more
- Volunteers
- 517 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Immersive Virtual Reality Bicycling for Persons With Parkinson's Disease
This study has three objectives about persons with Parkinson's Disease during bicycling: 1. Determine the effect of visual feedback and competition during virtual bicycling on neuromuscular and cardiovascular intensity 2.
- Trial name
- NCT05160025
- Testing
- Virtual reality bicycling
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Rutgers, The State University of New Jersey
Parkinson Disease
Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa
The survey is conducted to collect safety and effectiveness information in Parkinson's Disease patients treated with Pramipexole without concomitant L-Dopa supplementation in the daily clinical settings in Japan.
- Trial name
- NCT00613301
- Where
- 119 sites in Japan
- Volunteers
- 416 people
- Sponsor
- Boehringer Ingelheim
Urothelial Cancer
Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
This is a study using pembrolizumab (MK-3475, KEYTRUDA®) for first-line treatment of participants with advanced/unresectable (inoperable) or metastatic urothelial cancer who are ineligible for cisplatin-based therapy.
- Trial name
- NCT02335424
- Testing
- pembrolizumab
- Volunteers
- 374 people
- Sponsor
- Merck Sharp & Dohme LLC
Triple Negative Breast Cancer (TNBC)
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
The study will consist of two parts. In Part 1, the safety of pembrolizumab (MK-3475) in combination with one of three different chemotherapies will be assessed in the treatment of locally recurrent inoperable or metastatic…
- Trial name
- NCT02819518
- Testing
- Pembrolizumab, Nab-paclitaxel, Paclitaxel
- Volunteers
- 882 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Carcinoma
Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
In this study, participants with stage IV Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) colorectal carcinoma (CRC) will be randomly assigned to receive either pembrolizumab or the Investigator's…
- Trial name
- NCT02563002
- Testing
- mFOLFOX6, FOLFIRI, Pembrolizumab
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
Participants with Stage IV nonsquamous non-small cell lung cancer (NSCLC) without prior systemic treatment will be treated with standard of care pembrolizumab combined with platinum-doublet chemotherapy for 4 cycles, then…
- Trial name
- KEYNOTE-782 (NCT03664024)
- Testing
- Pembrolizumab, Pemetrexed, Carboplatin
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 118 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease
A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa
This is a Phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the effects of 100 mg safinamide, administered orally once daily (OD), in Chinese Parkinson's disease (PD) patients, experiencing…
- Trial name
- NCT03881371
- Testing
- Safinamide
- Where
- 31 sites in China
- Volunteers
- 307 people
- Sponsor
- Zambon SpA
Parkinson's Disease
Telephone-linked Home-based Exercise Training in PD
This project is investigating whether a home-based exercise program will reduce depression in patients with Parkinson's disease.
- Trial name
- NCT02898740
- Testing
- Structural exercise, Health education
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Parkinson's Disease (PD)
Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin
The purpose of this study is to investigate CYP2C9 inhibition by BIA 9-1067 through the assessment of its effect on the pharmacokinetics of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT02169440
- Testing
- BIA 9-1067, Warfarin
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
Cognitive Rehabilitation for PD
To investigate the effectiveness of a novel compensatory cognitive rehabilitation program for individuals with Parkinson's disease (PD) and mild cognitive impairment (MCI).
- Trial name
- CogSMART-PD (NCT03335150)
- Testing
- CogSMART-PD, Supportive Care
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- VA Office of Research and Development
Urothelial Cancer
A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Participants with metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy will be randomly assigned to receive Investigator's choice of paclitaxel…
- Trial name
- NCT02256436
- Testing
- pembrolizumab, paclitaxel, vinflunine
- Volunteers
- 542 people
- Sponsor
- Merck Sharp & Dohme LLC